T Minematsu

Summary

Affiliation: Astellas Pharma Inc
Country: Japan

Publications

  1. doi request reprint Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 2 1 6, Kashima, Yodogawa ku, Osaka Shi, Osaka 532 8514, Japan
    Drug Metab Dispos 38:249-59. 2010
  2. doi request reprint Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel sma
    Tsuyoshi Minematsu
    Astellas Pharma Inc, 2 1 6, Kashima, Yodogawa ku, Osaka Shi, Osaka 532 8514 Japan
    Drug Metab Dispos 38:1-4. 2010
  3. doi request reprint Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 8, Azusawa 1 chome, Itabashi ku, Tokyo 174 8511, Japan
    Drug Metab Dispos 37:619-28. 2009
  4. ncbi request reprint Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans
    T Minematsu
    Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Tokyo, Japan
    Xenobiotica 38:1191-202. 2008
  5. doi request reprint Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 8 Azusawa 1 chome, Itabashiku, Tokyo 174 8511, Japan
    Drug Metab Dispos 36:1496-504. 2008
  6. doi request reprint Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 1 8 Azusawa, Itabashi ku, Tokyo 174 8511, Japan
    Biomed Chromatogr 22:763-9. 2008
  7. ncbi request reprint Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers
    T Minematsu
    Drug Metabolism Laboratories, Yamanouchi Pharmaceutical, Co Ltd, Tokyo, Japan
    Xenobiotica 35:359-71. 2005
  8. ncbi request reprint Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients
    T Minematsu
    Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    Transplant Proc 36:1506-11. 2004
  9. ncbi request reprint YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
  10. ncbi request reprint Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872)
    Kin Ya Sohda
    Drug Metabolism Laboratories, Drug Development Division, Yamanouchi Pharmaceutical Co Ltd, 1 1 8 Azusawa, Itabashi ku, Tokyo 174 8511, Japan
    Chem Pharm Bull (Tokyo) 52:1322-5. 2004

Collaborators

Detail Information

Publications11

  1. doi request reprint Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 2 1 6, Kashima, Yodogawa ku, Osaka Shi, Osaka 532 8514, Japan
    Drug Metab Dispos 38:249-59. 2010
    ..The model developed here would be helpful in predicting drug-drug interactions and in the design of dose regimens that avoid drug-drug interactions...
  2. doi request reprint Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel sma
    Tsuyoshi Minematsu
    Astellas Pharma Inc, 2 1 6, Kashima, Yodogawa ku, Osaka Shi, Osaka 532 8514 Japan
    Drug Metab Dispos 38:1-4. 2010
    ....
  3. doi request reprint Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 8, Azusawa 1 chome, Itabashi ku, Tokyo 174 8511, Japan
    Drug Metab Dispos 37:619-28. 2009
    ..To summarize, YM155 was taken up into cancer cells in a carrier-mediated manner and with a similar affinity among all the cancer cell lines tested. An influx transporter(s) may contribute to this process...
  4. ncbi request reprint Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans
    T Minematsu
    Drug Metabolism Research Laboratories, Drug Discovery Research, Astellas Pharma Inc, Tokyo, Japan
    Xenobiotica 38:1191-202. 2008
    ....
  5. doi request reprint Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 8 Azusawa 1 chome, Itabashiku, Tokyo 174 8511, Japan
    Drug Metab Dispos 36:1496-504. 2008
    ..The interspecies differences in the excretion of zonampanel between rats and humans may thus be explained by those in the substrate selectivity and tissue distribution of OATs...
  6. doi request reprint Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma
    Tsuyoshi Minematsu
    Drug Metabolism Research Laboratories, Astellas Pharma Inc, 1 1 8 Azusawa, Itabashi ku, Tokyo 174 8511, Japan
    Biomed Chromatogr 22:763-9. 2008
    ..05 ng/mL. Good intra- and inter-day assay precision (within 7.4% RSD) and accuracy (within +/-12.3%) were obtained. The extraction recovery was 66.2%. The method was successfully applied to preclinical pharmacokinetic studies in dogs...
  7. ncbi request reprint Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers
    T Minematsu
    Drug Metabolism Laboratories, Yamanouchi Pharmaceutical, Co Ltd, Tokyo, Japan
    Xenobiotica 35:359-71. 2005
    ..These results show that virtually all of the administered YM872 remains unchanged, with urinary excretion representing the major elimination pathway. The high renal clearance implies tubular secretion of this drug...
  8. ncbi request reprint Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients
    T Minematsu
    Department of Pharmacy, University of Tokyo Hospital, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    Transplant Proc 36:1506-11. 2004
    ..Because FK506 highly and saturably binds in blood cells, a change in hematocrit value (Hct) may affect FK506 pharmacokinetics. Therefore, we investigated effects of Hct on FK506 pharmacokinetics...
  9. ncbi request reprint YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Takahito Nakahara
    Institute for Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Cancer Res 67:8014-21. 2007
    ..Further extensive investigation of YM155 in many types of cancer, including HRPC, seems to be worthwhile to develop this novel therapeutic approach...
  10. ncbi request reprint Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872)
    Kin Ya Sohda
    Drug Metabolism Laboratories, Drug Development Division, Yamanouchi Pharmaceutical Co Ltd, 1 1 8 Azusawa, Itabashi ku, Tokyo 174 8511, Japan
    Chem Pharm Bull (Tokyo) 52:1322-5. 2004
    ..Therefore, the proposed metabolic pathway of YM872 in rats involves the reduction of the nitro group to a hydroxyamino group and then subsequent reduction to an amino group...
  11. ncbi request reprint Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters
    Tadashi Hashimoto
    Drug Metabolism Laboratories, Drug Development Division, Yamanouchi Pharmaceutical Co, Ltd, 1 8, Azusawa 1 chome, Itabashi ku, Tokyo 174 8511, Japan
    Drug Metab Dispos 32:1096-102. 2004
    ....